Budipine: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
| verifiedrevid = 437186133 | | verifiedrevid = 437186133 | ||
| IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref> | | IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref> | ||
| image = Budipine. | | image = Budipine.png | ||
<!--Clinical data--> | <!--Clinical data--> |
Latest revision as of 13:43, 10 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.446 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Budipine |
Articles |
---|
Most recent articles on Budipine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Budipine at Clinical Trials.gov Clinical Trials on Budipine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Budipine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Budipine Risk calculators and risk factors for Budipine
|
Healthcare Provider Resources |
Causes & Risk Factors for Budipine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Budipine is an antiparkinson agent.
Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]
See also
References
- ↑ Martndale: The Complete Drug Reference, 35th Ed.
- ↑ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
- ↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
- ↑ "umm.edu".
- ↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Antiparkinsonian agents
- Piperidines
- Drug